ORGS - Orgenesis Inc.
| Previous Close | 4.8500 |
| Open | 4.8700 |
| Bid | 4.6500 x 1400 |
| Ask | 5.0900 x 1300 |
| Day's Range | 4.5500 - 4.8700 |
| 52 Week Range | 2.3500 - 6.4900 |
| Volume | 35,960 |
| Avg. Volume | 69,039 |
| Market Cap | 73.533M |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4340 |
| Earnings Date | Feb 13, 2020 - Feb 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
- GlobeNewswire
Orgenesis Announces Collaboration with The John Hopkins University for the Development and Processing of Cell and Gene Based Clinical Therapeutics
Orgenesis Inc. (ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced that it has entered into a collaboration agreement with the John Hopkins University (“JHU”) to utilize Orgenesis’ POCare platform to develop and supply a variety of cell and gene therapies and technologies, including cell-based immunotherapy technologies.
- GlobeNewswire
Orgenesis Completes Sale of Masthercell Subsidiary; Receives Approximately $127 Million in Net Proceeds
Orgenesis Inc. (ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced the completion of the sale of its Masthercell Global, Inc. subsidiary, a contract development manufacturing organization (CDMO), to Catalent Pharma Solutions. Upon closing, Orgenesis received net proceeds of approximately $127 million from the transaction.
- Benzinga
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
- GlobeNewswire
Orgenesis Announces Agreement for the Sale of Masthercell Global, its Contract Development and Manufacturing Organization (CDMO) Subsidiary
GERMANTOWN, Md., Feb. 03, 2020 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell.
- Business Wire
Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.
- GlobeNewswire
Orgenesis Inc. Announces $9.2 Million Private Placement
GERMANTOWN, Md., Jan. 21, 2020 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis Appoints Industry Veteran Mario Philips to its Board of Directors
GERMANTOWN, Md., Jan. 13, 2020 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis Announces Addition of University of California, Davis, to its Point of Care Network; UC Davis Health to Utilize Orgenesis’ Point of Care Platform for the Development, Commercialization and Supply of Cell and Gene Therapy Products
Orgenesis Inc. (ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services, as well as localized point-of-care development and processing centers through its subsidiary Orgenesis Maryland, Inc., today announced the addition of the University of California, Davis (UC Davis) to its Point of Care (“POCare”) Network. Under the collaboration agreement, UC Davis Health will utilize Orgenesis’ POCare platform to develop, commercialize and supply cell and gene products and therapies.
- GlobeNewswire
Orgenesis Announces Receipt of the $6.6 Million Second Milestone Payment into Masthercell Global Subsidiary
Orgenesis Inc. (ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services, as well as localized point-of-care development and processing centers through its subsidiary, Orgenesis Maryland, Inc., today announced that it has received the second milestone payment of $6.6 million from its strategic partnership with Great Point Partners, LLC (“GPP”) in accordance with the Stock Purchase Agreement (“SPA”), announced on June 28, 2018. Per the SPA, GPP provided for a $25 million investment into Masthercell Global, consisting of an upfront payment of $11.8 million in June 2018 and $13.2 million in tranched payments, subject to Masthercell Global achieving specified EBITDA and revenues targets on or before December 31, 2019.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Superior Industries International Inc. (SUP)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- GlobeNewswire
Orgenesis and Theracell to Launch Point of Care Cell and Gene Therapy Centers within HYGEIA Group’s Hospital Network in Greece
GERMANTOWN, Md., Dec. 06, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis Ranked 5th Fastest Growing Technology Company in Maryland and 208th in North America on Deloitte's 2019 Technology Fast 500™
GERMANTOWN, Md., Nov. 26, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis Inc. Reminds Stockholders to Vote in Favor of All Proposals at the Annual Meeting of Stockholders to be Held on November 26, 2019
GERMANTOWN, Md., Nov. 22, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis CEO Appears as a Guest on i24 News Network
GERMANTOWN, Md., Nov. 13, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis Third Quarter 2019 Revenue Increases 46% to a Record $9.1 Million
GERMANTOWN, MD, Nov. 08, 2019 -- Orgenesis Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized Contract.
- GlobeNewswire
Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board
GERMANTOWN, Md., Oct. 31, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
GERMANTOWN, Md., Oct. 28, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis Announces Co-Development Agreement with Accellix
GERMANTOWN, Md., Oct. 16, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- Simply Wall St.
Is Orgenesis Inc. (NASDAQ:ORGS) Excessively Paying Its CEO?
Vered Caplan has been the CEO of Orgenesis Inc. (NASDAQ:ORGS) since 2013. First, this article will compare CEO...
- GlobeNewswire
Orgenesis to Present at the 2019 Janney Healthcare Conference
GERMANTOWN, Md., Sept. 09, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
- GlobeNewswire
Orgenesis Reorganizes Its Israel and Korea Subsidiaries to Support Continued Growth
GERMANTOWN, Md., Aug. 14, 2019 -- Orgenesis Inc. (NASDAQ: ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development.
- GlobeNewswire
Orgenesis Second Quarter 2019 Revenue Increases 95% to a Record $7.8 Million
Generates $1 Million in Sales through New POCare Platform Ends Quarter with Over $16 Million of Cash and Cash Equivalents GERMANTOWN, Md., Aug. 12, 2019 -- Orgenesis.
- GlobeNewswire
Orgenesis Granted FDA Orphan Drug Designation for Autologous Insulin Producing Cells in the Treatment of Severe Hypoglycemia-Prone Diabetes Resulting from Total Pancreatectomy
GERMANTOWN, Md., June 17, 2019 -- Orgenesis Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a developer, manufacturer and service provider of advanced cell therapies,.
- GlobeNewswire
Orgenesis First Quarter 2019 Revenue Increases 177% to a Record $7.3 Million
GERMANTOWN, Md., May 09, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a developer, manufacturer and service provider of advanced cell therapies, today.
